EP3429584A4 - Compositions and methods for the treatment of presbyopia - Google Patents

Compositions and methods for the treatment of presbyopia Download PDF

Info

Publication number
EP3429584A4
EP3429584A4 EP17767172.4A EP17767172A EP3429584A4 EP 3429584 A4 EP3429584 A4 EP 3429584A4 EP 17767172 A EP17767172 A EP 17767172A EP 3429584 A4 EP3429584 A4 EP 3429584A4
Authority
EP
European Patent Office
Prior art keywords
presbyopia
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17767172.4A
Other languages
German (de)
French (fr)
Other versions
EP3429584A1 (en
Inventor
Gerald Horn
Lee NORDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presbyopia Therapies Inc
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/073,139 external-priority patent/US9833441B2/en
Priority claimed from US15/073,089 external-priority patent/US9844537B2/en
Priority claimed from US15/235,431 external-priority patent/US10052313B2/en
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of EP3429584A1 publication Critical patent/EP3429584A1/en
Publication of EP3429584A4 publication Critical patent/EP3429584A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
EP17767172.4A 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia Withdrawn EP3429584A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/073,139 US9833441B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/073,089 US9844537B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/235,431 US10052313B2 (en) 2013-08-28 2016-08-12 Compositions and methods for the treatment of presbyopia
PCT/US2017/021244 WO2017160548A1 (en) 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia

Publications (2)

Publication Number Publication Date
EP3429584A1 EP3429584A1 (en) 2019-01-23
EP3429584A4 true EP3429584A4 (en) 2019-11-13

Family

ID=59852351

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17767172.4A Withdrawn EP3429584A4 (en) 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia

Country Status (6)

Country Link
EP (1) EP3429584A4 (en)
JP (1) JP2019508472A (en)
CN (1) CN108883102A (en)
CA (1) CA3017755A1 (en)
MX (1) MX2018011300A (en)
WO (1) WO2017160548A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026884B2 (en) * 2018-01-24 2021-06-08 Eye Therapies Llc Methods for improving vision
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
EP4003341A4 (en) * 2019-07-26 2023-08-30 Allergan Sales, LLC Compositions and methods for treatment of presbyopia
AU2021369566A1 (en) * 2020-11-02 2023-06-22 Visus Therapeutics, Inc. Degradant compound in a medicament
CN114588156A (en) * 2022-04-22 2022-06-07 温州医科大学附属眼视光医院 Ophthalmic preparation and application thereof in treating presbyopia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008278A1 (en) * 2013-08-28 2016-01-14 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia
US20160346259A1 (en) * 2013-08-28 2016-12-01 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
BR112016014404A2 (en) * 2013-12-18 2017-08-08 Gnt Llc COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160008278A1 (en) * 2013-08-28 2016-01-14 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia
US20160346259A1 (en) * 2013-08-28 2016-12-01 Presbyopia Therapies, LLC Compositions and Methods for the Treatment of Presbyopia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017160548A1 *

Also Published As

Publication number Publication date
CN108883102A (en) 2018-11-23
MX2018011300A (en) 2019-02-18
WO2017160548A1 (en) 2017-09-21
JP2019508472A (en) 2019-03-28
CA3017755A1 (en) 2017-09-21
EP3429584A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
EP3675882A4 (en) Methods and compositions for treatment of microbiome-associated disorders
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
EP3426250A4 (en) Methods of treatment
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
EP3408344A4 (en) Well treatment methods and compositions
EP3423100A4 (en) Compositions for treating inflammation and methods of treating the same
EP3538189A4 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
EP3429584A4 (en) Compositions and methods for the treatment of presbyopia
EP3352749A4 (en) Compounds and compositions for the treatment of ocular disorders
EP3863630A4 (en) Compositions and methods for the treatment of presbyopia
EP3651747A4 (en) Compositions and methods for the treatment of eye disorders
EP3720421A4 (en) Compositions and methods for the treatment of metabolic conditions
EP3310783A4 (en) Methods and compositions for the prevention and treatment of hearing loss
EP3687524A4 (en) Compositions and methods for treating ophthalmic conditions
EP3094284A4 (en) Compositions and methods for the treatment of intraocular neovascularization and/or leakage
EP3522873A4 (en) Compositions and methods for the treatment of xerostomia
EP3368048A4 (en) Methods and compositions for the treatment of amyloidosis
IL272121A (en) Composition and methods for the treatment of myopia
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3452044A4 (en) Compositions and methods for the treatment of cancer
EP3341006A4 (en) Compositions and methods for the treatment of neurodamage
ZA201900984B (en) Methods and compositions for the treatment of warts
EP3206708A4 (en) Methods and compositions for the treatment of radiation-related disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/439 20060101AFI20191004BHEP

Ipc: A61K 47/38 20060101ALI20191004BHEP

Ipc: A61P 27/10 20060101ALI20191004BHEP

Ipc: A61K 9/00 20060101ALI20191004BHEP

Ipc: A61K 31/4409 20060101ALI20191004BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603